URI Description
sg:pub.10.1038/542148a Treaty to stop biopiracy threatens to delay flu vaccines
sg:pub.10.1038/482142a Lab flu may not aid vaccines
sg:pub.10.1186/1756-0500-3-92 A universal long-term flu vaccine may not prevent severe epidemics
sg:pub.10.1038/nbt1109-971 Steve Reed
sg:pub.10.1038/438023a Race is on for flu vaccine
sg:pub.10.1038/nrd3414 Cell-based flu vaccines ready for US prime time
sg:pub.10.1057/palgrave.jcb.3040160 Growth drivers and resistors of the influenza market: The importance of cell culture flu
sg:pub.10.1007/s002620000145 The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines
sg:pub.10.1007/bf03405265 Cost Analysis of Public Health Influenza Vaccine Clinics in Ontario
sg:pub.10.2165/00128415-200912760-00010 MHRA announce safety monitoring programme for swine flu vaccines
sg:pub.10.1007/bf03289193 GIVE UP THE BATTLE WITH FLU VACCINES?
sg:pub.10.1038/nbt0213-93a Egg-free flu vaccines
sg:pub.10.2165/00151234-200404500-00023 Pharmacist provision of vaccines linked to higher 'flu vaccine coverage
sg:pub.10.1007/bf03280638 Canadian government and Shire agree on 'flu vaccines
sg:pub.10.1007/bf03300336 THREE NEW FLU VACCINES TO CHOOSE FROM THIS WINTER
sg:pub.10.1007/s10534-009-9212-9 Are toxic biometals destroying your children’s future?
sg:pub.10.2165/00128413-200615620-00040 Flu vaccines for paediatrics: intranasal CAIV-T vs TIV
sg:pub.10.2165/00128413-199811610-00014 New flu and pneumococcal vaccines coming soon?
sg:pub.10.2165/00128413-200615410-00002 Whole-virus bird flu vaccines could increase supply
sg:pub.10.1038/475142b Immunology: Crystal ball for flu vaccines
sg:pub.10.2165/00128413-200715760-00004 WHO: pandemic avian flu vaccines promising, but production low
sg:pub.10.2165/00128415-201214260-00004 Novartis flu vaccines banned in Italy, Switzerland & Canada
sg:pub.10.2165/00128415-201214270-00006 Switzerland & Canada lift ban on Novartis flu vaccines
sg:pub.10.1038/495284d Immunology: Flu vaccines may improve with age
sg:pub.10.2165/00128415-200912770-00001 Swine flu vaccines: baseline rates of possible AEs estimated
sg:pub.10.1038/460562a US puts flu vaccines on trial
sg:pub.10.1186/s12879-017-2341-9 Evaluation of the immunogenicity and safety of different doses and formulations of a broad spectrum influenza vaccine (FLU-v) developed by SEEK: study protocol for a single-center, randomized, double-blind and placebo-controlled clinical phase IIb trial
sg:pub.10.1038/nbt1205-1457 Cautious industry welcome for US flu vaccine plan
sg:pub.10.1007/bf01719684 Vaccine manufacture at the time of a pandemic influenza
sg:pub.10.1038/nm0412-471 Four-strain flu vaccines coming to a pharmacy near you
sg:pub.10.1038/nrd3457 Cell-based flu vaccines ready for US prime time
sg:pub.10.1038/nbt0213-98 Inovio
sg:pub.10.1186/gb-spotlight-20030410-01 Quick custom flu vaccines
sg:pub.10.1038/scibx.2008.51 Sublingual delivery of influenza vaccines
sg:pub.10.1038/nm0113-4 Cell-based vaccines yield only modest advances for seasonal flu
sg:pub.10.1038/nri2345 Mucosal vaccines: NKT cells help fight flu
sg:pub.10.1038/news070924-3 Do flu vaccines work for the elderly?
sg:pub.10.1023/a:1010321128990 Pneumococcal Immunizations at Flu Clinics: The Impact of CommunityampHyphen;Wide Outreach
sg:pub.10.1038/435415a Controlling avian flu at the source
sg:pub.10.1038/nm0909-984 Boosting our best shot
sg:pub.10.1186/1471-2296-7-2 Determinants of adult vaccination at inner-city health centers: A descriptive study
sg:pub.10.1186/1471-2334-14-319 Difference in immune response in vaccinated and unvaccinated Swedish individuals after the 2009 influenza pandemic
sg:pub.10.1186/1472-6963-14-35 “It’s easier in pharmacy”: why some patients prefer to pay for flu jabs rather than use the National Health Service
sg:pub.10.1186/1471-2458-11-15 Determinants of adults' intention to vaccinate against pandemic swine flu
sg:pub.10.1038/nbt.2733 Vaccines for pandemics
sg:pub.10.1385/comp:32:2:90 Avian flu
sg:pub.10.1038/nm1109-1251 Attacking the flu: Neutralizing antibodies may lead to 'universal' vaccine
sg:pub.10.1038/551310a Influenza: A broadly protective antibody
sg:pub.10.1023/a:1027312223474 Rectal Immunization for Induction of Specific Antibody in the Genital Tract of Women
sg:pub.10.1007/s11096-016-0255-z Who uses pharmacy for flu vaccinations? Population profiling through a UK pharmacy chain
URI Description
sg:pub.10.1007/978-1-4614-5278-2_2 Operations Research and Homeland Security: Overview and Case Study of Pandemic Influenza
sg:pub.10.1007/978-3-319-05512-1_12 Conclusions and Future Perspectives
sg:pub.10.1007/5584_2014_31 Detection of Influenza and Other Respiratory Viruses Carried Out in the Influenza Project – Monitoring Vaccine Effectiveness (I-MOVE)
sg:pub.10.1007/978-94-011-6630-0_7 The New York Swine Influenza Immunization Program
sg:pub.10.1007/978-981-10-0080-5_5 Hybrid Model Based Influenza Detection with Sentiment Analysis from Social Networks
sg:pub.10.1007/978-3-319-20448-2_1 Introduction
sg:pub.10.1007/978-3-319-10951-0_87 The Roles of Mass Media and Personal Information Sources on Adoption of Pandemic Vaccines
sg:pub.10.1007/978-3-319-62701-4_19 MapReduce and Spark-Based Analytic Framework Using Social Media Data for Earlier Flu Outbreak Detection
sg:pub.10.1007/978-3-642-00499-5_15 The Common Cold and the Flu
sg:pub.10.1007/978-3-319-59952-6_14 Influenza Vaccines
sg:pub.10.1057/9781137339218.0010 Five Visualizing the Spanish Flu Nation
sg:pub.10.1007/978-1-4020-8617-5_13 Shaping Ethical Guidelines for an Influenza Pandemic
sg:pub.10.1007/978-1-4419-1132-2_15 New Strategies to Overcome the Drawbacks of Currently Available Flu Vaccines
sg:pub.10.1007/978-0-387-09560-8_5 Encephalitis
sg:pub.10.1057/9781137339218_2 A Mundane Mystery: Framing the Flu in the First Epidemic Wave
sg:pub.10.1007/978-3-642-25731-5_13 Detecting Unexpected Correlation between a Current Topic and Products from Buzz Marketing Sites
sg:pub.10.1007/978-94-007-6162-9_1 Introduction of Influenza A (H1N1)
sg:pub.10.1007/978-981-13-2083-5_3 Invasions of Small Numbers: How Many Virus Particles Does It Take to Infect Someone with the Flu?
sg:pub.10.1007/3-540-36583-4_14 Mass Vaccination: Solutions in the Skin
sg:pub.10.1007/978-3-642-38256-7_24 Online Social Networks Flu Trend Tracker: A Novel Sensory Approach to Predict Flu Trends
sg:pub.10.1057/9781137339218_1 Introduction: Epidemic Genre and Spanish Flu Narrative(s)
sg:pub.10.1007/978-3-540-72608-1_4 A Model for Characterizing Annual Flu Cases
sg:pub.10.1007/978-3-319-11119-3_13 Detect and Analyze Flu Outlier Events via Social Network
sg:pub.10.1007/978-3-642-12683-3_38 Deciphering the Swine-Flu Pandemics of 1918 and 2009
sg:pub.10.1057/9781137009326_7 Epilogue: Swine Flu Redux
sg:pub.10.1007/978-3-642-79136-9_6 Isospecific Pseudo-Helical Zirconocenium Catalysts
sg:pub.10.1057/9780230281660_1 Gender and the Language of Illness
sg:pub.10.1007/978-981-10-1023-1_30 SIR Model of Swine Flu in Shimla
sg:pub.10.1007/978-3-319-04211-4_6 International Control of Epidemic Diseases from a Historical and Cultural Perspective
sg:pub.10.1007/978-3-7643-8371-8_10 MF59: A safe and potent oil in water emulsion adjuvant for influenza vaccines, which induces enhanced protection against virus challenge
sg:pub.10.1007/978-3-642-30961-8_21 A Generalized Directive-Based Approach for Accelerating PDE Solvers
sg:pub.10.1057/9781137520166_6 Pandemic Influenza: ‘The Most Feared Security Threat’
sg:pub.10.1007/978-94-007-2780-9_2 Issue Framing: Making Your Concerns a Global Priority
sg:pub.10.1007/978-3-319-05512-1_9 Public Health Importance and Pandemic Potentials/Threats of Influenza Viruses
sg:pub.10.1007/978-3-0346-0279-2_14 Emulsion-Based Adjuvants for Improved Influenza Vaccines
sg:pub.10.1057/9781137004109.0008 Metaphors and Topoi of H1N1 (Swine Flu) Political Cartoons
sg:pub.10.1007/978-3-0346-0279-2_6 Influenza Vaccines Have a Short but Illustrious History of Dedicated Science Enabling the Rapid Global Production of A/Swine (H1N1) Vaccine in the Current Pandemic
sg:pub.10.1057/9781137339218.0009 Four Figuring (out) the Epidemic
sg:pub.10.1057/9781137339218.0008 Three A Tale of Two States
sg:pub.10.1057/9780230304628_8 ‘This Revived Old Plague’1: Coping with Flu
sg:pub.10.1057/9781137339218.0007 Two Of Borders and Bodies
sg:pub.10.1057/9781137339218.0005 Introduction
sg:pub.10.1057/9781137339218.0011 Conclusion
sg:pub.10.1057/9781137339218.0006 One A Mundane Mystery
sg:pub.10.1007/978-81-322-0740-5_68 Variation in Active Site Amino Residues of H1N1 Swine Flu Neuraminidase
sg:pub.10.1007/978-3-642-70007-1_34 Guillain-Barré Syndrome Following (A/New Jersey/76) Influenza (Swine Flu) Vaccine: Epidemic or Artifact?
sg:pub.10.1007/978-3-319-09891-3_16 Predicting Flu Epidemics Using Twitter and Historical Data
sg:pub.10.1007/978-3-642-60178-1_16 New C1-Symmetric Metallocenes for the Polymerization of Olefins
sg:pub.10.1057/9781137004109_4 Metaphors and Topoi of H1N1 (Swine Flu) Political Cartoons: A Cross-cultural Analysis
sg:pub.10.1057/978-1-349-95145-1_13 Pandemics and Dual-Use Research
URI Description
sg:grant.6729683 Understanding and Controlling Influenza
sg:grant.2458998 Boosting Flu Vaccination without Adjuvant Injection
sg:grant.3929289 Using mathematical models to optimize Ontario's emergency antiviral stockpile in time for the next flu pandemic
sg:grant.6715148 Mucosal vaccine for influenza on inactivated virus and mannan
sg:grant.2688107 Manipulating natural host immunoregulation via IDO during viral Infection
sg:grant.3829744 PLANT-BASED BIOPRODUCTION OF CHICKEN IL-12 ADJUVANT FOR BIRD FLU VACCINE
sg:grant.4979100 Transgenic chicken coccidia stimulate protective anti-bird flu mucosal immune response mechanism
sg:grant.2666106 CD4 T cell protection in the lung
sg:grant.2459894 Development of a novel adjuvant for vaccine sparing
sg:grant.2770898 Correlation of immunogenicity with microarray analysis of vector mutants to improve live recombinant poxvirus vaccines in poultry
sg:grant.6729737 Development of a novel mannan-based avian influenza vaccine
sg:grant.5977328 Development of influenza vaccine obtained by adding a heterologous antigen as an adjuvant
sg:grant.4962853 Who pathogenic avian influenza H5N1 virus vaccine Universal Basic Research
sg:grant.2354933 Chemically Programmed Immunity
sg:grant.3797051 A “Universal” Influenza Vaccine through Synthetic, Dendritic Cell-Targeted, Self-Replicating RNA Vaccines
sg:grant.2458176 CD4 effector contraction in influenza
sg:grant.2459401 Overcoming Immunosenescence by Nanoparticle-Mediated Activation
sg:grant.3571453 Terahertz Spectroscopy of Mass-Manufactured Viral Vaccines
sg:grant.7208444 Mechanism of action of angiotensin-converting enzyme 2 in acute lung injury induced by H5N1 HPAI virus
sg:grant.2687921 Live attenuated vaccines for epidemic and pandemic flu
sg:grant.3806952 Deciphering the signals regulating flu-specific resident memory T cells
sg:grant.2459430 Building novel vaccines on a borrowed coat
sg:grant.2687949 DNA Vaccine for Seasonal &Pandemic Influenza
sg:grant.2459193 Subunit Vaccines for Brucella Pathogens
sg:grant.2760578 The cellular immune response to HIV-1, HIV-2, influenza and Dengue virus infection
sg:grant.2435055 T Cell Memory to Pathogens: Generation and Function
sg:grant.7014662 Molecular mechanism and intervention study on the formation of cysticercosis in larvae of
sg:grant.2723393 Influenza Vaccine Development
sg:grant.4929925 Canine Influenza virus pathogenesis and molecular evolution
sg:grant.2762029 Replication of influenza virus at the molecular level
sg:grant.2561911 Immunogenicity & efficacy of chimeric flu virus expressing Ab42 B cell epitope
sg:grant.2754060 MRC Centre for Outbreak Analysis and Modelling Renewal
sg:grant.2764589 The regulation of influenza A virus replication and transcription
sg:grant.2666754 Alternative Pathways for CD4+ T Cell Epitope Generation from Influenza Antigens
sg:grant.2757751 FLU PANDEMIC: Study of behavioural/biological determinants of transmission to inform seasonal/pandemic planning
sg:grant.2771883 Immunopathogenesis of Emerging Infections Diseases in Humans
sg:grant.3787609 Novel strategies to combat future influenza pandemics
sg:grant.3560736 Multivalent proteins for the prophylaxis of influenza
sg:grant.3623800 NOX1 and NOX2 as Therapeutic Targets in Influenza
sg:grant.3766442 Development of a combined Influenza/SARS vaccine
sg:grant.2459964 Antibody Responses in HIV and Aging
sg:grant.5004327 The role of traditional Chinese medicine to prevent influenza and correlation with mucosal immunity
sg:grant.4055053 Bik Promotes Cleavage of Viral Proteins to Enhance Influenza A Virus Infection
sg:grant.3090317 Avian Flu: Modeling, Analysis, and Simulations
sg:grant.2600622 Receptor tyrosine kinase signaling and influenza viral RNA synthesis
sg:grant.5017435 Mechanism "berberine and fluconazole" synergistic anti-Candida albicans resistant "bubble"
sg:grant.2567392 Influenza Transmission: Exploratory Visualization and Knowledge Discovery of Indi
sg:grant.7202920 Study on the Activity and Immune Mechanism of "Aromatic and Furile" Chinese Herbs as Mucous Adjuvant to Influenza Vaccine
sg:grant.2598062 Early Response to Agents Causing Flu Like Symptoms
sg:grant.2767973 Contribution of NKT cells to modulation of immunepathology in influenza infection
URI Description
sg:patent.WO-2012060678-A2 NOVEL VACCINES AGAINST THE A/H1N1 PANDEMIC FLU VIRUS
sg:patent.WO-2014200325-A3 CONSORTIUM OF THE RECOMBINANT INFLUENZA A VIRUSES FLU-NS1-124- L7/L12-H5N1, FLU-NS1-124-OMP16-H5N1, FLU-NS1-124-L7/L12-H1N1 AND FLU-NS1- 124-OMP16-H1N1, FAMILY ORTOMYXOVIRIDAE, GENUS INFLUENZAVIRUS, EXPRESSING BRUCELLA IMMUNODOMINANT PROTEINS DESTINED TO GENERATE A VACCINE AGAINST BRUCELLOSIS
sg:patent.WO-2014200325-A2 CONSORTIUM OF THE RECOMBINANT INFLUENZA A VIRUSES FLU-NS1-124- L7/L12-H5N1, FLU-NS1-124-OMP16-H5N1, FLU-NS1-124-L7/L12-H1N1 AND FLU-NS1- 124-OMP16-H1N1, FAMILY ORTOMYXOVIRIDAE, GENUS INFLUENZAVIRUS, EXPRESSING BRUCELLA IMMUNODOMINANT PROTEINS DESTINED TO GENERATE A VACCINE AGAINST BRUCELLOSIS
sg:patent.US-20120225068-A1 MONOCLONAL ANTIBODIES AS A MEDICAMENT FOR THE THERAPEUTIC AND/OR PROPHYLACTIC TREATMENT OF SWINE-ORIGIN INFLUENZA A (H1N1) VIRUS (S-OIV) INFECTIONS
sg:patent.WO-2017137753-A1 IMPROVED FLU VACCINE YIELD
sg:patent.WO-2007067966-A1 METHOD AND FORMULA FOR PREVENTION OF COLD AND FLU AND SUPPRESSION OF RELATED SYMPTOMS
sg:patent.WO-2011074928-A1 A RECOMBINANT A/ASTANARG/6:2/2009 M-12-09/D FLU VIRUS STRAIN PRODUCED BY A REVERSE GENETICS METHOD FROM A HIGHLY PATHOGENIC DONOR STRAIN A/CHICKEN/ASTANA/6/05 (H5N1) AND A HIGHLY REPRODUCTIVE DONOR STRAIN A/PUERTO RICO/8/34 (H1N1) FROM THE ORTHOMYXOVIRIDAE FAMILY OF THE GENUS INFLUENZA VIRUS TYPE A WHICH IS DEPOSITED IN THE MICROORGANISM COLLECTION OF THE SCIENCE COMMITTEE AT THE MINISTRY OF EDUCATION AND SCIENCE OF THE REPUBLIC OF KAZAKHSTAN STATE ENTERPRISE SUBSIDIARY OF THE SCIENTIFIC RESEARCH INSTITUTE FOR BIOLOGICAL SAFETY PROBLEMS AT THE REPUBLICAN STATE ENTERPRISE OF THE NATIONAL CENTRE FOR BIOTECHNOLOGY OF THE REPUBLIC OF KAZAKHSTAN AND CAN BE USED IN BIOTECHNOLOGY FOR THE PRODUCTION OF DIAGNOSTIC AND VACCINE PREPARATIONS AGAINST A/H5N1 FLU
sg:patent.US-9079944-B2 Influenza A virus vaccines and inhibitors
sg:patent.EP-2535405-A4 A RECOMBINANT A/ASTANARG/6:2/2009 M-12-09/D FLU VIRUS STRAIN PRODUCED BY A REVERSE GENETICS METHOD FROM A HIGHLY PATHOGENIC DONOR STRAIN A/CHICKEN/ASTANA/6/05 (H5N1) AND A HIGHLY REPRODUCTIVE DONOR STRAIN A/PUERTO RICO/8/34 (H1N1) FROM THE ORTHOMYXOVIRIDAE FAMILY OF THE GENUS INFLUENZA VIRUS TYPE A WHICH IS DEPOSITED IN THE MICROORGANISM COLLECTION OF THE SCIENCE COMMITTEE AT THE MINISTRY OF EDUCATION AND SCIENCE OF THE REPUBLIC OF KAZAKHSTAN STATE ENTERPRISE SUBSIDIARY OF THE SCIENTIFIC RESEARCH INSTITUTE FOR BIOLOGICAL SAFETY PROBLEMS AT THE REPUBLICAN STATE ENTERPRISE OF THE NATIONAL CENTRE FOR BIOTECHNOLOGY OF THE REPUBLIC OF KAZAKHSTAN AND CAN BE USED IN BIOTECHNOLOGY FOR THE PRODUCTION OF DIAGNOSTIC AND VACCINE PREPARATIONS AGAINST A/H5N1 FLU
sg:patent.US-8796008-B2 Influenza A virus vaccines and inhibitors
sg:patent.WO-2011034528-A1 COLD AND FLU SYMPTOMATIC RELIEF COMPOSITION
sg:patent.WO-2012162828-A1 MATRIPTASE INHIBITORS AND USES THEREOF AGAINST ORTHOMYXOVIRIDAE INFECTIONS
sg:patent.WO-2008036809-A2 METHODS AND MATERIALS FOR REDUCING RISK OF COLD AND/OR FLU
sg:patent.US-9752149-B2 Matriptase inhibitors and uses thereof against orthomyxoviridae infections
sg:patent.WO-2003026567-A2 USE OF NEURAMINIDASE INHIBITORS TO PREVENT FLU ASSOCIATED BACTERIAL INFECTIONS
sg:patent.EP-0231374-A1 INSERTION INTO ANIMALS OF GENES CODING FOR INTERFERON-INDUCED PROTEINS
sg:patent.US-9365853-B2 Matriptase inhibitors and uses thereof against orthomyxoviridae infections
sg:patent.WO-2010128396-A3 GENERIC ASSAYS FOR DETECTION OF INFLUENZA VIRUSES
sg:patent.EP-2286823-A2 Use of Cistus incanus extracts for the preparation of a medicament for the prevention and/or treatment of influenza
sg:patent.WO-2010128396-A2 GENERIC ASSAYS FOR DETECTION OF INFLUENZA VIRUSES
sg:patent.US-9320713-B2 Nanoparticles and nanoparticle compositions
sg:patent.US-8916519-B2 Influenza A virus vaccines and inhibitors
sg:patent.US-20080292658-A1 Defective Influenza Virus Particles
sg:patent.US-8486406-B2 Monoclonal antibodies as a medicament for the therapeutic and/or prophylactic treatment of swine-origin influenza A (H1N1) virus (S-OIV) infections
sg:patent.US-8790621-B2 Nanoparticles and nanoparticle compositions
sg:patent.WO-1995001792-A1 H2 ANTAGONIST-ANTIHISTAMINE COMBINATIONS
sg:patent.US-10022366-B2 Extending and maintaining micropore viability of microneedle treated skin with lipid biosynthesis inhibitors for sustained drug delivery
sg:patent.US-9198955-B2 Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
sg:patent.US-6248721-B1 Method of using mouse model for evaluation of HIV vaccines
sg:patent.AU-2004279990-B2 Modified whole cell, cell extract and OMV-based vaccines
sg:patent.WO-2017009349-A1 HISTONE ANTI-CANCER VACCINES
sg:patent.EP-3118217-A1 HISTONE ANTI-CANCER VACCINES
sg:patent.EP-3094652-A4 NOVEL VACCINES AGAINST HPV AND HPV-RELATED DISEASES
sg:patent.WO-2007026247-A1 VACCINES CONTAINING CORYNEBACTERIUM DIPHTHERIAE PILI
sg:patent.US-20150343040-A1 Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
sg:patent.EP-2204187-A1 Human flu vaccine containing four influenza peptides
sg:patent.EP-2121011-B1 VACCINES INCLUDING ANTIGEN FROM FOUR STRAINS OF INFLUENZA VIRUS
sg:patent.EP-2722322-A2 1,3-DI-OXO-INDENE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS AN ANTIVIRAL, ACTIVE INGREDIENT
sg:patent.EP-1322326-A1 INNATE IMMUNE SYSTEM-DIRECTED VACCINES
sg:patent.US-20160346381-A1 POULTRY VIRUS VACCINES THAT ARE LIQUID STABLE
sg:patent.US-9827305-B2 Poultry virus vaccines that are liquid stable
sg:patent.US-9453055-B2 Method of producing japanese encephalitis vaccine stably storable over long time and use of the vaccine
sg:patent.WO-2016083287-A1 INACTIVATED EQUINE INFLUENZA VIRUS VACCINES
sg:patent.EP-1046909-B1 Method and apparatus for determining the Joule-Thomson coefficient of a fluid
sg:patent.US-20120177677-A1 ANTIGEN SPECIFIC MULTI EPITOPE-BASED ANTI-INFECTIVE VACCINES
sg:patent.WO-2007136300-A2 SUBSTITUTED INDOLES AND A METHOD FOR THE PRODUCTION AND USE THEREOF
sg:patent.EP-2722322-A4 1,3-DI-OXO-INDENE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS AN ANTIVIRAL, ACTIVE INGREDIENT
sg:patent.EP-2535405-A1 A RECOMBINANT A/ASTANARG/6:2/2009 M-12-09/D FLU VIRUS STRAIN PRODUCED BY A REVERSE GENETICS METHOD FROM A HIGHLY PATHOGENIC DONOR STRAIN A/CHICKEN/ASTANA/6/05 (H5N1) AND A HIGHLY REPRODUCTIVE DONOR STRAIN A/PUERTO RICO/8/34 (H1N1) FROM THE ORTHOMYXOVIRIDAE FAMILY OF THE GENUS INFLUENZA VIRUS TYPE A WHICH IS DEPOSITED IN THE MICROORGANISM COLLECTION OF THE SCIENCE COMMITTEE AT THE MINISTRY OF EDUCATION AND SCIENCE OF THE REPUBLIC OF KAZAKHSTAN STATE ENTERPRISE SUBSIDIARY OF THE SCIENTIFIC RESEARCH INSTITUTE FOR BIOLOGICAL SAFETY PROBLEMS AT THE REPUBLICAN STATE ENTERPRISE OF THE NATIONAL CENTRE FOR BIOTECHNOLOGY OF THE REPUBLIC OF KAZAKHSTAN AND CAN BE USED IN BIOTECHNOLOGY FOR THE PRODUCTION OF DIAGNOSTIC AND VACCINE PREPARATIONS AGAINST A/H5N1 FLU
sg:patent.WO-1998044788-A2 ANIMAL MODEL FOR EVALUATION OF VACCINES
sg:patent.US-20150056247-A1 Sequential and repeated immunization with four or more vector-based HIV gene vaccines
URI Description
sg:clinicaltrial.NCT00985673 A Study to Evaluate the Safety and Immunogenicity of an A/California/7/2009 (H1N1)V-like Vaccine GSK2340274A or GSK2340273A Co-administered With Trivalent Inactivated Seasonal Influenza Vaccine in Adults 19 to 40 Years of Age
sg:clinicaltrial.NCT00620412 Lactobacillus GG to Enhance the Immunogenicity of Influenza Vaccine in Healthy Adults - Proof of Concept Study
sg:clinicaltrial.NCT00261001 A Randomized Comparative Phase I Study to Evaluate and to Compare the Safety and Immunogenicity of a Transcutaneous Mode of Administration of a Licensed Tetanus/Influenza Vaccine to the Conventional Intramuscular Route of Vaccine Administration in Healthy Volunteers and HIV-infected Patients
sg:clinicaltrial.NCT03180801 Phase IIb Study of the Efficacy of FLU-v, a Broad Spectrum Influenza Vaccine in an H1N1 Influenza Healthy Human Challenge Model
sg:clinicaltrial.NCT00216242 A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy of Fluviral™ Influenza Vaccine in Healthy Adults 18 to 49 Years of Age
sg:clinicaltrial.NCT02962908 A Randomised, Double-blind, Placebo-controlled, Single-centre Phase IIb Trial as Part of the EU-funded UNISEC Project to Assess the Immunogenicity and Safety of Different Formulations and Dosing Regimens of FLU-v Vaccine in Healthy Adults
sg:clinicaltrial.NCT02266277 System Alignment for VaccinE Delivery (SAVED): Improving Rates of Influenza and Pneumococcal Vaccination Through Patient Outreach, Improved Medical Record Accuracy and Targeted Physician Alerts.
sg:clinicaltrial.NCT01730144 Elucidation of the Mucosal Immune Responses to Live Attenuated Influenza Vaccine In Healthy Adults
sg:clinicaltrial.NCT00554333 An Open-label, Multi-centre, Randomised, Comparative Study of the Immunogenicity and Safety of an Inactivated Split-Virion Influenza Vaccine Administered by Intradermal Route (Flu-ID 15μg) Versus an Inactivated Adjuvanted Influenza Vaccine Administered by Intramuscular Route in Subjects 65 Years of Age or Older
sg:clinicaltrial.NCT03186781 VRC 316: A Phase I Open-Label Clinical Trial To Evaluate Dose, Safety, Tolerability, And Immunogenicity Of An Influenza HA Ferritin Vaccine, Alone Or In Prime-Boost Regimens With An Influenza DNA Vaccine In Healthy Adults
sg:clinicaltrial.NCT02987374 Pilot Study in Young Adults to Examine the Kinetics of Changes in the B-cell Repertoire Following TIV Immunization
sg:clinicaltrial.NCT00995527 Characterization of the Innate Immune Response in Healthy NIH Employees at Baseline and After Immunization With the H1N1 Vaccine
sg:clinicaltrial.NCT02765126 Clifford Craig Vaccine Trial Centre: Heterologous Effect of Diptheria, Tetanus, Acellular Pertussis Vaccination on Influenza Vaccine Challenge in the Elderly
sg:clinicaltrial.NCT01761435 Randomized, Comparative and Prospective Clinical Trial Evaluating Efficacy and Safety of a Dose of Seasonal Flu Vaccine Compared to Two Doses of Vaccine for Prevention of Influenza in Solid Organ Transplant Recipients
sg:clinicaltrial.NCT00137579 Phase IV, Simple Blind, 2-Parallel Groups Randomized Trial to Evaluate the Safety and Effectiveness of the Intramuscular Vs Subcutaneous Route for the Administration of the Anti-Flu Vaccine in Patients Receiving Oral Anticoagulation
sg:clinicaltrial.NCT02207413 Safety and Immunogenicity Study of GSK Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK23211381A) Manufactured With a New Process in Adults and Children
sg:clinicaltrial.NCT01086657 VRC 310: An Open-Label, Randomized Ph I: Healthy Adults of Prime-Boost Intervals w/Monovalent Influenza Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc), Administered Alone or Following Recombinant H5 DNA Vaccine
sg:clinicaltrial.NCT01389518 Evaluation of the Efficacy and Safety of Fixed Combination of Paracetamol, Chlorpheniramine and Phenylephrine in the Treatment of Symptomatic Common Cold and Flu Syndrome in Adults
sg:clinicaltrial.NCT01440387 A Phase IIIA Study of Immunogenicity and Safety of GSK Biologicals' Quadrivalent Split Virion Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
sg:clinicaltrial.NCT00408109 VRC 304: A Phase I Study of the Safety and Immunogenicity of a Recombinant DNA Plasmid Vaccine (VRC-AVIDNA036-00-VP), Encoding for the Influenza Virus H5 Hemagglutinin Protein in Healthy Adults
sg:clinicaltrial.NCT00953667 The Genetics of Evoked Responses to Niacin and Endotoxemia: The GENE Study
sg:clinicaltrial.NCT01398150 Cranberry Enhances Human Immune Function and Reduces Illness
sg:clinicaltrial.NCT03699839 Reducing the Burden of Influenza After Solid-Organ Transplantation: the STOP-FLU Trial [Swiss Trial in Solid Organ Transplantation on Prevention of Influenza]
sg:clinicaltrial.NCT03159702 Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation
sg:clinicaltrial.NCT00489931 A Phase I Open-Label Study of the Safety and Immunogenicity of a Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for the Influenza Virus H5 Hemagglutinin Protein Administered Intradermally in Healthy Adults
sg:clinicaltrial.NCT03309618 Improving Arterial Wall Characteristics in Patients After Myocardial Infarction With a Very Low Dose of Fluvastatin and Valsartan: Proof-of-concept Study
sg:clinicaltrial.NCT00023504 Evaluation of Immune Response to Vaccines in Primary Immune Disorders
sg:clinicaltrial.NCT01187017 A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia
sg:clinicaltrial.NCT03144518 A Feasibility Trial of a Brief Positive Affect Intervention to Improve the Effectiveness of Influenza Vaccine Response in Older Adults.
sg:clinicaltrial.NCT01005095 A One Year Prospective, Randomized, Double Blind Interventional Study to Assess Tolerability, Quality of Life and Immunomodulation With Interferon Beta Combined With Vitamin D in Patients With Relapsing Remitting Multiple Sclerosis
sg:clinicaltrial.NCT01145976 Randomized Comparison of Cyclophosphamide Versus Fludarabine in Addition to Anti-thymocyte Globulin for the Conditioning Therapy in Allogeneic Hematopoietic Cell Transplantation for Adult Acquired Aplastic Anemia
sg:clinicaltrial.NCT02543918 Vaccination Response Following Administration of Ixekizumab to Healthy Subjects
sg:clinicaltrial.NCT00979407 Immunological Equivalence Between GSK2340272A and GSK2340274A Influenza Vaccines in Adults Aged 18 to 60 Years
sg:clinicaltrial.NCT00972309 A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer
sg:clinicaltrial.NCT00334529 Evaluation of Alternative Oseltamivir (Tamiflu[R]) Dosing Strategies for Use During Influenza Prophylaxis
sg:clinicaltrial.NCT00766662 Intermittent Preventive Treatment in Infant in Mali
sg:clinicaltrial.NCT00001439 A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant
sg:clinicaltrial.NCT00001409 A Phase I/II Pilot Study of the Safety of the Adoptive Transfer of Syngeneic Gene-Modified Cytotoxic T Lymphocytes in HIV Infected Identical Twins
sg:clinicaltrial.NCT01706302 Burden of Respiratory Syncytial Virus (RSV) in the United Kingdom, 1995 to 2009
sg:clinicaltrial.NCT00258934 Immunogenicity Study of the Influenza Vaccine in Adults
sg:clinicaltrial.NCT01159990 A Randomized, Double Blind Phase 1b Trial to Examine the Influence of Antigenic Competition on the Immunogenicity of HIV-1 Gag/Pol: A Comparison of rAd5 Gag/Pol Env A/B/C to rAd5 Gag/Pol
sg:clinicaltrial.NCT02946190 A Phase II Randomized, Observer-blind Controlled Pilot Study to Compare the Safety and Immunogenicity of Acellular Pertussis Vaccines Including Chemically or Genetically-detoxified Pertussis Toxin in Adolescents Aged 11-15 Years Previously Immunized With Acellular Pertussis Vaccines
sg:clinicaltrial.NCT03384316 Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer
sg:clinicaltrial.NCT00121160 Can Stress Management Improve Vaccine Immune Response
sg:clinicaltrial.NCT02408913 VRC 208: Phase 1/1b Open-Label Clinical Trial to Evaluate Dose, Safety and Immunogenicity of Recombinant Modified Vaccinia Virus Ankara Ebola Vaccine,VRC-EBOMVA079-00-VP, Administered Alone or as Boost to cAd3-Ebola Vaccines in Healthy Adults
sg:clinicaltrial.NCT01132859 VRC 900: Evaluation of Tissue-Specific Immune Responses in Adults 18 Years of Age and Older
sg:clinicaltrial.NCT02710045 The Interaction Between Live and Killed Vaccines: the Effect of the DTP Combined Vaccine on T Cell Memory Following Measles Vaccination
sg:clinicaltrial.NCT01360112 Malaria Transmission Blocking Assay Development and Gametocyte Carriage in a Vaccine Testing Site in Mali
sg:clinicaltrial.NCT01619462 A Study of Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines to Inform Policy Regarding Pneumococcal Vaccination of Papua New Guinean Children
sg:clinicaltrial.NCT00558051 Phase I Evaluation of Semi-continuous Alpha-type-1 Dendritic Cell-based Vaccines in Patients With Metastatic Colorectal Cancer
URI Description
sg:pub.10.1057/9781137339218 The Spanish Flu
sg:pub.10.1385/1597451681 DNA Vaccines
sg:pub.10.1385/1592596886 DNA Vaccines
sg:pub.10.1007/978-1-4615-0105-3 DNA Vaccines
sg:pub.10.1007/0-387-27545-2 Tumor Immunology and Cancer Vaccines
sg:pub.10.1385/1592591485 Meningococcal Vaccines
sg:pub.10.1007/978-3-0348-0980-1 Fish Vaccines
sg:pub.10.1007/978-1-4615-0053-7 New Bacterial Vaccines
sg:pub.10.1007/978-1-4939-6481-9 RNA Vaccines
sg:pub.10.1007/978-1-4939-6869-5 Recombinant Virus Vaccines
sg:pub.10.1007/978-1-4939-7104-6 Vaccines for Invasive Fungal Infections
sg:pub.10.1007/978-1-59259-265-4 Combination Vaccines, Development, Clinical Research, and Approval
sg:pub.10.1007/978-1-4615-3848-6 Vaccines, Recent Trends and Progress
sg:pub.10.1007/978-1-4757-0283-5 Immunological Adjuvants and Vaccines
sg:pub.10.1007/978-3-0346-0279-2 Influenza Vaccines for the Future
sg:pub.10.1007/978-1-4614-5380-2 Novel Immune Potentiators and Delivery Technologies for Next Generation Vaccines
sg:pub.10.1007/978-1-4939-0850-9 Genetically Engineered Plants as a Source of Vaccines Against Wide Spread Diseases, An Integrated View
sg:pub.10.1007/978-1-4757-9268-3 New Vaccines and Chemotherapy
sg:pub.10.1007/978-3-7091-0439-2 Gene Vaccines
sg:pub.10.1007/978-981-13-0484-2 HIV Vaccines and Cure, The Path Towards Finding an Effective Cure and Vaccine
sg:pub.10.1007/978-1-4684-0997-0 Cell Substrates, Their Use in the Production of Vaccines and Other Biologicals
sg:pub.10.1007/978-1-4939-3387-7 Vaccine Design, Methods and Protocols: Volume 1: Vaccines for Human Diseases
sg:pub.10.1007/978-3-642-20054-0 Vaccines against Allergies
sg:pub.10.1007/978-1-4684-5739-1 Protein Design and the Development of New Therapeutics and Vaccines
sg:pub.10.1007/978-1-4939-2383-0 Lyophilized Biologics and Vaccines, Modality-Based Approaches
sg:pub.10.1007/978-1-4419-1108-7 Vaccines: A Biography
sg:pub.10.1007/978-3-319-00978-0 Molecular Vaccines, From Prophylaxis to Therapy - Volume 2
sg:pub.10.1007/978-3-0346-0277-8 Replicating Vaccines, A New Generation
sg:pub.10.1007/978-3-319-59952-6 Pediatric Vaccines and Vaccinations
sg:pub.10.1007/978-1-4939-2874-3 Carbohydrate-Based Vaccines, Methods and Protocols
sg:pub.10.1007/978-1-4615-3410-5 Genetically Engineered Vaccines
sg:pub.10.1007/978-1-4899-1382-1 Novel Strategies in the Design and Production of Vaccines
sg:pub.10.1007/978-3-319-90137-4 Prospects of Plant-Based Vaccines in Veterinary Medicine
sg:pub.10.1007/978-1-4613-9226-2 Veterinary Vaccines
sg:pub.10.1007/978-3-642-59955-2 Vaccines
sg:pub.10.1007/978-1-4615-2948-4 New Generation Vaccines, The Role of Basic Immunology
sg:pub.10.1007/978-1-4939-3389-1 Vaccine Design, Methods and Protocols, Volume 2: Vaccines for Veterinary Diseases
sg:pub.10.1007/978-3-642-27470-1 Ricin and Shiga Toxins, Pathogenesis, Immunity, Vaccines and Therapeutics
sg:pub.10.1007/978-1-4939-0410-5 DNA Vaccines, Methods and Protocols
sg:pub.10.1007/978-3-7091-0709-6 Development of Novel Vaccines, Skills, Knowledge and Translational Technologies
sg:pub.10.1007/978-3-642-59951-4 Defense of Mucosal Surfaces: Pathogenesis, Immunity and Vaccines
sg:pub.10.1007/978-3-319-23910-1 Cancer Vaccines
sg:pub.10.1007/978-3-540-70868-1 Plant-produced Microbial Vaccines
sg:pub.10.1007/978-3-642-23693-8 Mucosal Vaccines, Modern Concepts, Strategies, and Challenges
sg:pub.10.1007/978-3-319-23150-1 Biologics to Treat Substance Use Disorders, Vaccines, Monoclonal Antibodies, and Enzymes
sg:pub.10.1007/978-3-540-92165-3 Vaccines for Pandemic Influenza
sg:pub.10.1007/978-94-011-5404-8 Animal Cell Technology, From Vaccines to Genetic Medicine
sg:pub.10.1007/978-1-4939-2815-6 Malaria Vaccines, Methods and Protocols
sg:pub.10.1007/978-1-4612-2992-6 Anti-Idiotypic Vaccines
sg:pub.10.1007/978-1-59259-680-5 Handbook of Cancer Vaccines
URI Description
sg:ontologies/subjects/influenza-virus Influenza virus
sg:ontologies/subjects/protein-vaccines Protein vaccines
sg:ontologies/subjects/vaccines Vaccines
sg:ontologies/subjects/dna-vaccines DNA vaccines
sg:ontologies/subjects/inactivated-vaccines Inactivated vaccines
sg:ontologies/subjects/cell-vaccines Cell vaccines
sg:ontologies/subjects/peptide-vaccines Peptide vaccines
sg:ontologies/subjects/tumour-vaccines Tumour vaccines
sg:ontologies/subjects/live-attenuated-vaccines Live attenuated vaccines
sg:ontologies/subjects/rotavirus Rotavirus
sg:ontologies/subjects/rna-vaccines RNA vaccines
sg:ontologies/subjects/biomaterials-vaccines Biomaterials – vaccines
sg:ontologies/subjects/recombinant-vaccine Recombinant vaccine
sg:ontologies/subjects/conjugate-vaccines Conjugate vaccines
sg:ontologies/subjects/malaria Malaria
sg:ontologies/subjects/applied-immunology Applied immunology
sg:ontologies/subjects/cancer-immunotherapy Cancer immunotherapy
sg:ontologies/subjects/biologics Biologics
sg:ontologies/subjects/adjuvants Adjuvants
sg:ontologies/subjects/translational-immunology Translational immunology
sg:ontologies/subjects/immunotherapy Immunotherapy
sg:ontologies/subjects/public-health Public health
sg:ontologies/subjects/adenovirus Adenovirus
sg:ontologies/subjects/cancer-therapy Cancer therapy
sg:ontologies/subjects/biomaterials Biomaterials
sg:ontologies/subjects/biolistics Biolistics
sg:ontologies/subjects/microbiology Microbiology
sg:ontologies/subjects/immunology Immunology
URI Description
sg:ontologies/subjects/influenza-virus Influenza virus
sg:ontologies/subjects/protein-vaccines Protein vaccines
sg:ontologies/subjects/vaccines Vaccines
sg:ontologies/subjects/dna-vaccines DNA vaccines
sg:ontologies/subjects/inactivated-vaccines Inactivated vaccines
sg:ontologies/subjects/cell-vaccines Cell vaccines
sg:ontologies/subjects/peptide-vaccines Peptide vaccines
sg:ontologies/subjects/tumour-vaccines Tumour vaccines
sg:ontologies/subjects/live-attenuated-vaccines Live attenuated vaccines
sg:ontologies/subjects/rotavirus Rotavirus
sg:ontologies/subjects/rna-vaccines RNA vaccines
sg:ontologies/subjects/biomaterials-vaccines Biomaterials – vaccines
sg:ontologies/subjects/recombinant-vaccine Recombinant vaccine
sg:ontologies/subjects/conjugate-vaccines Conjugate vaccines
sg:ontologies/subjects/malaria Malaria
sg:ontologies/subjects/applied-immunology Applied immunology
sg:ontologies/subjects/cancer-immunotherapy Cancer immunotherapy
sg:ontologies/subjects/biologics Biologics
sg:ontologies/subjects/adjuvants Adjuvants
sg:ontologies/subjects/translational-immunology Translational immunology
sg:ontologies/subjects/immunotherapy Immunotherapy
sg:ontologies/subjects/public-health Public health
sg:ontologies/subjects/adenovirus Adenovirus
sg:ontologies/subjects/cancer-therapy Cancer therapy
sg:ontologies/subjects/biomaterials Biomaterials
sg:ontologies/subjects/biolistics Biolistics
sg:ontologies/subjects/microbiology Microbiology
sg:ontologies/subjects/immunology Immunology
URI Description
sg:journal.1031279 Journal of Immune Based Therapies and Vaccines
sg:journal.1052948 Tropical Diseases, Travel Medicine and Vaccines
sg:journal.1032339 Genetic Vaccines and Therapy
sg:journal.1050793 Current Clinical Microbiology Reports
sg:journal.1284501 npj Vaccines
sg:journal.1021426 Current Opinion in Molecular Therapeutics
sg:journal.1020815 Pediatric Drugs
sg:journal.1106201 Molecular Biotechnology
sg:journal.1094644 Pharmaceutical Research
sg:journal.1097703 Molecular Genetics, Microbiology and Virology
sg:journal.1050275 Infectious Diseases and Therapy
URI Description
grid-institutes:grid.419647.9 Research Institute of Vaccines and Sera. Mechnikov of the Russian Academy of Medical Sciences
grid-institutes:grid.420435.4 Global Vaccines (United States)
grid-institutes:grid.488906.b Institute of Virology, Vaccines and Sera “Torlak”
grid-institutes:grid.475282.e International Society for Vaccines
grid-institutes:grid.475702.3 Trust for Vaccines & Immunization
grid-institutes:grid.489072.0 National Institute for Control of Vaccines and Biologicals
grid-institutes:grid.497430.d Bharat Serums and Vaccines (India)
grid-institutes:grid.475363.0 Global Alliance for Livestock Veterinary Medicines
URI Description
sg:person.01164406425.50 Willem Jan Flu
sg:person.057634154.45 H Flu
sg:person.053773054.34 PC Flu
sg:person.0607262351.06 Hans C Flu
sg:person.013236451654.89 Nucleic Acid Delivery Devices For Hiv Vaccines Workshop Group
URI Description
grid-institutes:grid.475282.e International Society for Vaccines
grid-institutes:grid.475702.3 Trust for Vaccines & Immunization
grid-institutes:grid.475363.0 Global Alliance for Livestock Veterinary Medicines
URI Description
grid-institutes:grid.420435.4 Global Vaccines (United States)
grid-institutes:grid.497430.d Bharat Serums and Vaccines (India)
URI Description
grid-institutes:grid.419647.9 Research Institute of Vaccines and Sera. Mechnikov of the Russian Academy of Medical Sciences
grid-institutes:grid.489072.0 National Institute for Control of Vaccines and Biologicals
URI Description
grid-institutes:grid.488906.b Institute of Virology, Vaccines and Sera “Torlak”